HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its quarterly earnings results on Monday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by $0.07.

HTG Molecular Diagnostics (NASDAQ:HTGM) opened at 1.9601 on Wednesday. HTG Molecular Diagnostics has a 12-month low of $1.85 and a 12-month high of $5.93. The firm’s 50-day moving average price is $2.36 and its 200 day moving average price is $2.55. The company’s market capitalization is $13.82 million.

Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)

Several research firms have recently issued reports on HTGM. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of HTG Molecular Diagnostics in a research report on Thursday, October 13th. Rodman & Renshaw began coverage on HTG Molecular Diagnostics in a research report on Monday, August 22nd. They issued a “buy” rating and a $5.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $5.25.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

5 Day Chart for NASDAQ:HTGM

Receive News & Stock Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related stocks with our FREE daily email newsletter.